Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Protalix Biotherapeutics (PLX)
:PLX
Holding PLX?
Track your performance easily
Earnings Data
Report Date
Mar 13, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
0.08Last Year’s EPS
-0.03Same Quarter Last Year
Based on 0 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 07, 2018
|% Change Since: 75.00%
|Next Earnings Date:Aug 09, 2018
Earnings Call Sentiment|Positive
The earnings call highlighted significant revenue growth, successful completion of a crucial clinical trial, and an improved financial position by becoming debt-free. However, there were some reductions in R&D service revenues and an increase in income tax expenses. Overall, the positive aspects such as revenue growth and debt clearance strongly outweigh the negative aspects.Company Guidance
During the Protalix BioTherapeutics Q3 2024 earnings call, significant guidance was provided on their ongoing projects and financial performance. The company completed all eight cohorts in the Phase I clinical trial for PRX-115, their candidate for treating uncontrolled gout, involving 64 subjects, with promising preliminary results showing dose-dependent reduction in plasma uric acid levels. Plans are underway for a Phase II trial in the second half of 2025. Financially, Protalix reported a 75% increase in goods sales revenue to $17.8 million, driven by a $6.8 million rise in sales to Chiesi and $1.1 million to Pfizer, while research and development expenses decreased by 19% to $3 million. The company also achieved a net income of $3.2 million, reversing a previous net loss, and is now debt-free after repaying all outstanding promissory notes. These developments position Protalix to advance their pipeline, focusing on renal rare diseases and leveraging their platform technology.Significant Revenue Growth
Revenues from selling goods increased by $7.6 million or 75% during the three months ended September 30, 2024, primarily from increased sales to Chiesi and Pfizer.
Completion of PRX-115 Phase I Trial
All cohorts of the Phase I trial of PRX-115 were completed with results showing promise for treating uncontrolled gout. The drug was well tolerated with only mild to moderate adverse events reported.
Debt-Free Status Achieved
Protalix repaid in full all outstanding principal and interest under the 7.5% senior secured convertible promissory notes, using available cash, leaving the company debt-free.
Net Income Improvement
The company reported a net income of $3.2 million for the three months ended September 30, 2024, compared to a net loss of $1.9 million for the same period in 2023.
---
PLX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
PLX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 14, 2024 | $1.24 | $1.41 | +13.71% |
| Aug 14, 2024 | $1.04 | $0.93 | -10.58% |
| May 10, 2024 | $1.25 | $1.10 | -12.00% |
| Mar 14, 2024 | $1.52 | $1.37 | -9.87% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Protalix Biotherapeutics (PLX) report earnings?
Protalix Biotherapeutics (PLX) is schdueled to report earning on Mar 13, 2025, TBA Not Confirmed.
What is Protalix Biotherapeutics (PLX) earnings time?
Protalix Biotherapeutics (PLX) earnings time is at Mar 13, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is PLX EPS forecast?
PLX EPS forecast for the fiscal quarter 2024 (Q4) is 0.08.
---